HUE039393T2 - Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck - Google Patents
Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neckInfo
- Publication number
- HUE039393T2 HUE039393T2 HUE14731782A HUE14731782A HUE039393T2 HU E039393 T2 HUE039393 T2 HU E039393T2 HU E14731782 A HUE14731782 A HU E14731782A HU E14731782 A HUE14731782 A HU E14731782A HU E039393 T2 HUE039393 T2 HU E039393T2
- Authority
- HU
- Hungary
- Prior art keywords
- paclitaxel
- cancer
- neck
- prevention
- head
- Prior art date
Links
- 229940116355 PI3 kinase inhibitor Drugs 0.000 title 1
- 229930012538 Paclitaxel Natural products 0.000 title 1
- 201000010536 head and neck cancer Diseases 0.000 title 1
- 208000014829 head and neck neoplasm Diseases 0.000 title 1
- 229960001592 paclitaxel Drugs 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1354211 | 2013-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE039393T2 true HUE039393T2 (en) | 2018-12-28 |
Family
ID=49620017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE14731782A HUE039393T2 (en) | 2013-05-07 | 2014-05-06 | Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20160082012A1 (en) |
| EP (1) | EP2994126B1 (en) |
| JP (2) | JP6643978B2 (en) |
| KR (1) | KR102356393B1 (en) |
| CN (1) | CN105228611B (en) |
| AU (1) | AU2014264318B2 (en) |
| BR (1) | BR112015027047A2 (en) |
| CA (1) | CA2909448C (en) |
| CY (1) | CY1120693T1 (en) |
| DK (1) | DK2994126T3 (en) |
| ES (1) | ES2688464T3 (en) |
| HR (1) | HRP20181489T1 (en) |
| HU (1) | HUE039393T2 (en) |
| LT (1) | LT2994126T (en) |
| MX (1) | MX2015015475A (en) |
| PL (1) | PL2994126T3 (en) |
| PT (1) | PT2994126T (en) |
| RU (1) | RU2672555C2 (en) |
| SI (1) | SI2994126T1 (en) |
| WO (1) | WO2014181252A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| WO2012118978A1 (en) * | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
-
2014
- 2014-05-06 PL PL14731782T patent/PL2994126T3/en unknown
- 2014-05-06 JP JP2016512460A patent/JP6643978B2/en active Active
- 2014-05-06 KR KR1020157031655A patent/KR102356393B1/en active IP Right Grant
- 2014-05-06 US US14/785,995 patent/US20160082012A1/en not_active Abandoned
- 2014-05-06 CA CA2909448A patent/CA2909448C/en active Active
- 2014-05-06 SI SI201430877T patent/SI2994126T1/en unknown
- 2014-05-06 BR BR112015027047A patent/BR112015027047A2/en not_active IP Right Cessation
- 2014-05-06 HU HUE14731782A patent/HUE039393T2/en unknown
- 2014-05-06 LT LTEP14731782.0T patent/LT2994126T/en unknown
- 2014-05-06 DK DK14731782.0T patent/DK2994126T3/en active
- 2014-05-06 AU AU2014264318A patent/AU2014264318B2/en active Active
- 2014-05-06 CN CN201480026309.6A patent/CN105228611B/en active Active
- 2014-05-06 MX MX2015015475A patent/MX2015015475A/en unknown
- 2014-05-06 RU RU2015152032A patent/RU2672555C2/en active
- 2014-05-06 EP EP14731782.0A patent/EP2994126B1/en active Active
- 2014-05-06 PT PT14731782T patent/PT2994126T/en unknown
- 2014-05-06 ES ES14731782.0T patent/ES2688464T3/en active Active
- 2014-05-06 WO PCT/IB2014/061239 patent/WO2014181252A1/en active Application Filing
-
2017
- 2017-03-06 US US15/450,727 patent/US9913846B2/en active Active
-
2018
- 2018-09-19 HR HRP20181489TT patent/HRP20181489T1/en unknown
- 2018-09-20 CY CY181100978T patent/CY1120693T1/en unknown
-
2019
- 2019-03-04 JP JP2019038619A patent/JP2019131559A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT2994126T (en) | 2018-09-25 |
| US20160082012A1 (en) | 2016-03-24 |
| CY1120693T1 (en) | 2019-12-11 |
| KR102356393B1 (en) | 2022-01-26 |
| CA2909448A1 (en) | 2014-11-13 |
| WO2014181252A1 (en) | 2014-11-13 |
| HRP20181489T1 (en) | 2018-11-16 |
| BR112015027047A2 (en) | 2017-07-25 |
| CN105228611B (en) | 2018-01-26 |
| AU2014264318B2 (en) | 2017-03-16 |
| KR20160005702A (en) | 2016-01-15 |
| US9913846B2 (en) | 2018-03-13 |
| ES2688464T3 (en) | 2018-11-02 |
| SI2994126T1 (en) | 2018-10-30 |
| RU2672555C2 (en) | 2018-11-16 |
| MX2015015475A (en) | 2016-03-21 |
| RU2015152032A (en) | 2017-06-13 |
| AU2014264318A1 (en) | 2015-10-22 |
| CA2909448C (en) | 2021-10-26 |
| DK2994126T3 (en) | 2018-09-24 |
| JP2019131559A (en) | 2019-08-08 |
| EP2994126A1 (en) | 2016-03-16 |
| EP2994126B1 (en) | 2018-06-20 |
| PT2994126T (en) | 2018-10-22 |
| JP6643978B2 (en) | 2020-02-12 |
| PL2994126T3 (en) | 2018-11-30 |
| CN105228611A (en) | 2016-01-06 |
| JP2016518400A (en) | 2016-06-23 |
| US20170173032A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304851A (en) | Tazemetostat in combination with a standard care agent for use in the treatment of cancer | |
| HK1223089A1 (en) | Kinase inhibitor and use thereof | |
| GB2513167B (en) | Tetrahydrocannabivarin for use in the treatment of nausea and vomiting | |
| PL3004108T3 (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | |
| HK1221144A1 (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer tor | |
| HK1223304A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| IL267238A (en) | Heparanase inhibitors and use thereof | |
| PL2984184T3 (en) | Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| LT3057589T (en) | (s)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IL248854A0 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| HK1223014A1 (en) | Therapeutic agents for use in the prophylaxis and or treatment of hyperkinetic movement disorders | |
| IL251407B (en) | Multivalent compounds for use in the treatment and prevention of brain damage | |
| HRP20181489T1 (en) | Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck | |
| IL267243A (en) | Heparanase inhibitors and use thereof | |
| IL245998B (en) | Pharmaceutical compositions for use in the treatment and prevention of metastatic cancer | |
| ZA201600894B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes | |
| GB201312131D0 (en) | Drug combination and its use in therapy | |
| GB201312128D0 (en) | Drug combination and its use in therapy | |
| GB201312129D0 (en) | Drug combination and its use in therapy | |
| HUE047636T2 (en) | Arginine for use in the treatment and/or prevention of osteoarthritis |